

Electronic supplementary material 2: Evidence-based secondary prevention medications after heart failure

Article title: Effect of cardiologist care on 6-month outcomes in patients discharged with heart failure: results from an observational study based on administrative data

Journal name: BMJ Open

Author names: Vera Maria Avaldi, Jacopo Lenzi, Stefano Urbinati, Dario Molinazzi, Carlo Descovich, Anselmo Campagna, Martina Taglioni, Angelo Fioritti, Maria Pia Fantini

Affiliation and e-mail of the corresponding author: University of Bologna, jacopo.lenzi2@unibo.it

Table 1 provides a full list of the drug therapies collected during the 6-month follow-up period following hospital discharge. Minimum effective doses used to calculate medication adherence are also reported. At the end of the document, we provide a complete list of references to clinical trials used to retrieve drugs and doses.

Table 1 Evidence-based secondary prevention medications after heart failure and minimum effective doses

ATC code	Name	Minimum effective dose
<i>β-blockers</i>		
C07AB02	Metoprolol	12.5 mg/die
C07AB07	Bisoprolol	1.25 mg/die
C07AG02	Carvedilol	6.25 mg/die
<i>ACEIs/ARBs</i>		
C09AA01	Captopril	12.5 mg/die
C09AA02	Enalapril	5 mg/die
C09AA03	Lisinopril	2.5 mg/die
C09AA04	Perindopril	2 mg/die
C09AA05	Ramipril	1.25 mg/die
C09AA06	Quinapril	5 mg/die
C09AA07	Benazepril	2.5 mg/die
C09AA08	Cilazapril	0.5 mg/die
C09AA09	Fosinopril	10 mg/die
C09BA02	Enalapril and diuretics	1 cpr/die
C09BA03	Lisinopril and diuretics	1 cpr/die
C09BA04	Perindopril and diuretics	1 cpr/die
C09BA05	Ramipril and diuretics	1 cpr/die
C09BA06	Quinapril and diuretics	1 cpr/die
C09BA09	Fosinopril and diuretics	1 cpr/die
C09BA12	Delapril and diuretics	1 cpr/die
C09BB02	Lisinopril e amlodipine	1 cpr/die
C09BB04	Perindopril e amlodipine	1 cpr/die
C09BB07	Ramipril e amlodipine	1 cpr/die
C09CA01	Losartan	12.5 mg/die
C09CA03	Valsartan	80 mg/die
C09CA06	Candesartan	4 mg/die
C09DA01	Losartan and diuretics	1 cpr/die
C09DA03	Valsartan and diuretics	1 cpr/die
C09DA06	Candesartan and diuretics	1 cpr/die
<i>Aldosterone antagonists</i>		
C03DA01	Spironolactone	25 mg/die
C03DA02	Potassium canrenoate	25 mg/die
C03DA03	Canrenone	25 mg/die
C03DA04	Eplerenone	25 mg/die

Abbreviations: ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.

References

Maia ER, Villacorta H, Subietta CG, et al. Use of propranolol in heart failure patients: safety, tolerability, and effects on left ventricular function. *Rev Port Cardiol* 2001;20:383–99.

Wilbert WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction $\geq 40\%$ treated with diuretics plus angiotensin-converting enzyme inhibitors. *Am J Cardiol* 1997;80:207–9.

Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344:1651–8.

[No authors listed]. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999;353:2001–7.

[No authors listed]. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999;353:9–13.

Sturm B, Pacher R, Strametz-Juranek J, et al. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. *Eur J Heart Fail* 2000;2:407–12.

Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. *Eur J Heart Fail* 2005;7:631–9.

Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215–25.

[No authors listed]. Captopril Multicenter Research Group. A placebo controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group. *J Am Coll Cardiol* 1983; 2:755–63

[No authors listed]. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med* 1991;325:293–302

Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation* 1999;100:2312–8.

Lechat P, Garnham J, Desche P, et al. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. *Am Heart J* 1993;126:798–826.

Gundersen T, Swedberg K, Amtorp O, et al. Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group. *Eur Heart J* 1994;15:1659–65.

[No authors listed]. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Lancet* 1993;342:821–8.

Riegger GA. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. *J Cardiovasc Pharmacol* 1990;15:S41–6.

Mirvis DM, Insel J, Boland MJ, et al. Chronic therapy for congestive heart failure with benazepril HCl, a new angiotensin converting enzyme inhibitor. *Am J Med Sci* 1990;300:354–60.

[No authors listed]. Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. The Cilazapril-Captopril Multicenter Group. *Cardiology* 1995;86 Suppl 1:34–40.

Bulpitt CJ, Fletcher AE, Dössegger L, et al. Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Cilazapril-Captopril Multicentre Group. *Heart* 1998;79:593–8.

Brown EJ Jr, Chew PH, MacLean A, et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Fosinopril Heart Failure Study Group. *Am J Cardiol* 1995;75:596–600.

- Erhardt L, MacLean A, Ilgenfritz J, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. *Eur Heart J* 1995;16:1892–9.
- Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. *New Engl J Med* 1995;332:80–5.
- Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997;349:747–52.
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study, ELITE II. *Lancet* 2000;355:1582–7.
- Cohn JN. Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. *Cardiology* 1999;91:19–22.
- Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001;345:1667–75.
- Kum LC, Yip GW, Lee PW. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure. *Int J Cardiol* 2008;125:16–21.
- Havranek EP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. *J Am Coll Cardiol* 1999;33:1174–81.
- Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Results of the CHARM low-left ventricular ejection fraction trials. *Circulation* 2004;110:2618–26.
- Dunselman PH. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. *Int J Cardiol* 2001;77:131–8.
- Sakata Y, Shiba N, Takahashi J. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. *Eur Heart J* 2015;36:915–23.
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;341:709–17.
- Vizzardi E, Nodari S, Carretta G. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. *Am J Med Sci* 2014;347:271–6.
- Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;364:11–21.